Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE) (SCATE)
|ClinicalTrials.gov Identifier: NCT01531387|
Recruitment Status : Terminated (inability to reach a satisfactory endpoint with respect to adequate recruitment)
First Posted : February 13, 2012
Results First Posted : December 9, 2015
Last Update Posted : February 8, 2016
|Condition or disease||Intervention/treatment||Phase|
|Sickle Cell Anemia||Drug: Hydroxyurea||Phase 3|
Results from previous studies confirm an increased risk of stroke among children with conditional TCD velocities. In addition, studies suggest that patients who were on observation alone, converted from conditional TCD (moderate risk category) to an abnormal TCD (with a much higher risk for primary stroke) within 30 months of initial identification of the conditional TCD velocity; this conversion led to initiation of chronic and indefinite transfusions in all cases. Preliminary data suggests that the risk of conversion to abnormal TCD velocities will be lower for subjects with conditional TCD velocities on hydroxyurea by at least three-fold. This important difference in conversion risk rate suggests that an alternative treatment could have a substantial and beneficial impact on patients with elevated TCD velocities.
An alternative treatment could protect the brain of patients with SCA and conditional TCD velocities who are at increased risk for stroke. The avoidance of chronic blood transfusions would be a great benefit for all children with sickle cell disease, especially those in developing countries where the blood supply may be less safe (in comparison with that in the US) or unavailable, and very costly.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||38 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Sparing Conversion to Abnormal TCD Elevation (SCATE) - a Phase III Clinical Trial to Compare Standard Care (Observation) With Alternative Therapy (Hydroxyurea) for Reducing the Risk of Converting to an Abnormal TCD Velocity in Children With Sickle Cell Anemia and Conditional Pre-treatment TCD Velocities.|
|Study Start Date :||May 2012|
|Actual Primary Completion Date :||January 2014|
|Actual Study Completion Date :||January 2014|
No Intervention: Standard Therapy: Observation
Half of the subjects will be randomized to clinical observation only, which includes monthly visits with clinical evaluations, laboratory tests, and TCD endpoint examinations
Half of the subjects will be randomized to hydroxyurea, taken as capsules (300 mg, 400 mg, or 500 mg), or as a liquid formulation (100 mg/mL). Hydroxyurea will be administered once daily by mouth. Subjects will be monitored monthly with clinical evaluations, laboratory tests, and TCD endpoint examinations.
Hydroxyurea will be administered once daily, in either capsule form (300mg, 400mg, or 500mg) or as a liquid formulation (100mg/ml). Dosing will commence at 20 mg/kg/day. Dose escalation will occur in 5 mg/kg/day increments, adjusting every 8 weeks unless hematological toxicity occurs.
- Conversion to Abnormal Maximum TAMV [ Time Frame: 30 months ]The primary endpoint of the SCATE trial is the cumulative incidence of conversion to abnormal maximum TAMV (time-averaged mean velocity) measured by transcranial doppler (TCD) ultrasonography. Subjects must have conditional velocities at baseline, defined as 170 - 199 cm/sec, which indicate moderate stroke risk. Abnormal velocities are defined as ≥ 200 cm/sec, which indicate high stroke risk. The number of conversions from conditional velocities to abnormal velocities in each treatment arm will be compared as the primary outcome.
- Serial TCD Velocities [ Time Frame: 30 months ]This secondary outcome measure will be the highest TAMV obtained in specific arteries. Serial TCD velocities are measured throughout the SCATE trial and will be compared to the baseline value.
- Cumulative Incidence of Neurological Events [ Time Frame: 30 months ]The cumulative incidence of neurological events as a secondary endpoint, which include both stroke and non-stroke neurological events, will be determined over the treatment period for both standard and alternative arms.
- Cumulative Incidence of Non-Neurological Events [ Time Frame: 30 months ]The cumulative incidence of non-neurological sickle cell-related events, including vaso-occlusion and splenic sequestration, will be estimated over the treatment period for both standard and alternative arms.
- Quality of Life [ Time Frame: 30 months ]Standard Quality of Life measure will be taken during specific time points, as well as one newly-developed Sickle Cell Disease Quality of Life measure.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01531387
|United States, Tennessee|
|St. Jude Children's Research Hospital|
|Memphis, Tennessee, United States, 38105|
|Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti (HEMORIO)|
|Centro, Rio de Janeiro, Brazil|
|Tropical Medicine Research Institute, University of the West Indies (UWI)|
|Mona, Kingston, Jamaica|
|Principal Investigator:||Russell E. Ware, MD, PhD||Children's Hospital Medical Center, Cincinnati|